2018 Volume 35 Issue 4 Pages 615-621
We treated 187 patients with onychomycosis of the great toenail using LUCONAC® Solution5% over a 17-month period. Of the 187 patients treated, 48 discontinued treatment and 26 were followed-up beyond 48 weeks. We observed similar results to those noted in the phase III trial; 11.5% of patients showed a marked improvement, 23.1% showed improvement, 23.1% showed marginal improvement, 26.9% showed no change, and 15.4% showed exacerbation. Therefore, approximately 42% of patients had no change or an exacerbation of the disease condition. Our results suggest that the type and severity of onychomycosis needs to be considered in each patient before establishing the treatment option for better management of the disease.